Skip to main navigation Skip to search Skip to main content

A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalanprednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma

  • Min Kyoung Kim
  • , Kihyun Kim
  • , Chang Ki Min
  • , Jae Yong Kwak
  • , Sang Byung Bae
  • , Sung Soo Yoon
  • , Je Jung Lee
  • , Ki Hwan Kim
  • , Seung Hyun Nam
  • , Yeung Chul Mun
  • , Hyo Jung Kim
  • , Sung Hwa Bae
  • , Ho Jin Shin
  • , Jung Hee Lee
  • , Joon Seong Park
  • , Seong Hyun Jeong
  • , Mark Hong Lee
  • , Yang Soo Kim
  • , Ho Sup Lee
  • , Keon Woo Park
    • Won Sik Lee, Sang Min Lee, Jeong Ok Lee, Myung Soo Hyun, Deog Yeon Jo, Sung Nam Lim, Jae Hoon Lee, Do Yeun Cho, Young Rok Do, Jeong A. Kim, Seong Kyu Park, Jin Seok Kim, Soo Jeong Kim, Hawk Kim, Hyeon Gyu Yi, Joon Ho Moon, Chul Won Choi, Sung Hyun Kim, Young Don Joo, Hoon Gu Kim, Byung Soo Kim, Moo Rim Park, Moo Kon Song, Su Youn Kim
  • Yeungnam University
  • Sungkyunkwan University
  • Jeonbuk National University
  • Soonchunhyang University
  • Seoul National University
  • Chonnam National University
  • Seoul National University Boramae Hospital
  • VHS Medical Center
  • Ewha Womans University
  • Hallym University
  • Catholic University of Daegu
  • Pusan National University
  • University of Ulsan
  • Ajou University
  • Konkuk University
  • Kosin University
  • Dankook University
  • Inje University
  • Chungnam National University
  • Gachon University
  • Konyang University
  • Keimyung University
  • The Catholic University of Korea
  • Yonsei University
  • Inha University
  • Kyungpook National University
  • Korea University
  • Dong-A University
  • Gyeongsang National University
  • Wonkwang University
  • Hanyang University
  • Johnson & Johnson

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalanprednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry